Protalix BioTherapeutics
PLX
PLX
33 hedge funds and large institutions have $8.72M invested in Protalix BioTherapeutics in 2016 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
33
Holders Change
+4
Holders Change %
+13.79%
% of All Funds
0.83%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
6
Reduced
7
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
VKH
26
Virtu KCG Holdings
New York
| $5K | -$424 | -95 | -8% |
|
|
PCM
27
Prelude Capital Management
New York
| $5K | +$5K | +1,050 | New |
|
28
Bank of America
Charlotte,
North Carolina
| $1K | -$333 | -80 | -25% |
|
|
CCM
29
Camber Capital Management
Boston,
Massachusetts
| – | -$7.43M | -1,327,500 | Closed |
|
30
Baillie Gifford & Co
Edinburgh,
United Kingdom
| – | -$3.56M | -636,136 | Closed |
|
31
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$29K | -5,070 | Closed |
|
|
FANJ
32
Financial Architects (New Jersey)
Marlton,
New Jersey
| – | -$6K | -1,000 | Closed |
|
33
Simplex Trading
Chicago,
Illinois
| – | -$3K | -561 | Closed |
|
|
EDRH
34
Edmond de Rothschild Holding
Chambesy,
Switzerland
| – | -$2K | -367 | Closed |
|